Last Updated: December 21, 2020
Result type: Reports
Generic Name: indacaterol glycopyrronium mometasone furoate
Indications: Indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months.
Last Updated: January 21, 2021
Result type: Reports
Generic Name: von Willebrand Factor [recombinant]
Indications: Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD
Last Updated: January 22, 2021
Result type: Reports
Generic Name: vedolizumab
Indications: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a TNFα antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.
Last Updated: December 23, 2020
Result type: Reports
Generic Name: ofatumumab
Indications: For the treatment of Relapsing Multiple Sclerosis (RMS).
Last Updated: December 24, 2020
Result type: Reports
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.
Last Updated: December 21, 2020
Result type: Reports
Generic Name: ranolazine
Indications: Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Last Updated: December 22, 2020
Result type: Reports
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)
Last Updated: December 23, 2020
Result type: Reports
Generic Name: durvalumab
Indications: IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Last Updated: December 22, 2020
Result type: Reports
Generic Name: ozanimod
Indications: For the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to decrease the frequency of clinical exacerbations.
Last Updated: December 23, 2020
Result type: Reports
Generic Name: pembrolizumab
Indications: For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)